This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Wade, A. G.
Right arrow Articles by Pedersen, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wade, A. G.
Right arrow Articles by Pedersen, T.

The British Journal of Psychiatry 170: 549-553 (1997)
© 1997 The Royal College of Psychiatrists

The effect of citalopram in panic disorder

AG Wade, U Lepola, HJ Koponen, V Pedersen and T Pedersen
Clydebank Health Centre, Dunbartonshire, Scotland.

BACKGROUND: Citalopram is a serotonin reuptake inhibitor which has been demonstrated to be highly selective and with a superior tolerability profile to the classical tricyclic antidepressants. This study was designed to test whether there was any difference in efficacy in the management of panic disorder (PD) between citalopram and placebo. METHOD: This was a double-blind, placebo and clomipramine controlled, parallel group eight-week study. A total of 475 patients with PD, with or without agoraphobia, were randomised to treatment with either placebo, clomipramine 60 or 90 mg/day, or citalopram 10 or 15 mg/day, or 20 or 30 mg/day, or 40 or 60 mg/day. Doses were increased over the first three weeks, stabilised during the fourth week and fixed between weeks five and eight. RESULTS: Treatment with citalopram at 20 or 30 mg, 40 or 60 mg and clomipramine were significantly superior to placebo, judged by the number of patients free of panic attacks in the week prior to the final assessment. All rating scales examined suggested that citalopram 20 or 30 mg was more effective than citalopram 40 or 60 mg. CONCLUSION: The most advantageous benefit/risk ratio for the treatment of PD was associated with citalopram 20 or 30 mg/day.


This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
C. Garcia-Leal, C. Del-Ben, F. Leal, F. Graeff, and F. Guimaraes
Escitalopram prolonged fear induced by simulated public speaking and released hypothalamic-pituitary-adrenal axis activation
J Psychopharmacol, May 1, 2010; 24(5): 683 - 694.
[Abstract] [PDF]

Home page
 J. Neurosci.Home page
A. M. Perkins, U. Ettinger, R. Davis, R. Foster, S. C. R. Williams, and P. J. Corr
Effects of Lorazepam and Citalopram on Human Defensive Reactions: Ethopharmacological Differentiation of Fear and Anxiety
J. Neurosci., October 7, 2009; 29(40): 12617 - 12624.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
M. W. Otto, K. S. Tuby, R. A. Gould, R. Y.S. McLean, and M. H. Pollack
An Effect-Size Analysis of the Relative Efficacy and Tolerability of Serotonin Selective Reuptake Inhibitors for Panic Disorder
Am J Psychiatry, December 1, 2001; 158(12): 1989 - 1992.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
D. MICHELSON, C. ALLGULANDER, K. DANTENDORFER, A. KNEZEVIC, D. MAIERHOFER, V. MICEV, V. R. PAUNOVIC, I. TIMOTIJEVIC, N. SARKAR, L. SKOGLUND, et al.
Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: Randomised, placebo-controlled trial
The British Journal of Psychiatry, December 1, 2001; 179(6): 514 - 518.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. M. Gorman
A 28-Year-Old Woman With Panic Disorder
JAMA, July 25, 2001; 286(4): 450 - 457.
[Full Text] [PDF]

Home page
 JAMAHome page
D. H. Barlow, J. M. Gorman, M. K. Shear, and S. W. Woods
Cognitive-Behavioral Therapy, Imipramine, or Their Combination for Panic Disorder: A Randomized Controlled Trial
JAMA, May 17, 2000; 283(19): 2529 - 2536.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
D. Michelson, R. B. Lydiard, M. H. Pollack, R. N. Tamura, S. L. Hoog, R. Tepner, M. A. Demitrack, G. D. Tollefson, and the Fluoxetine Panic Disorder Study Group
Outcome Assessment and Clinical Improvement in Panic Disorder: Evidence From a Randomized Controlled Trial of Fluoxetine and Placebo
Am J Psychiatry, November 1, 1998; 155(11): 1570 - 1577.
[Abstract] [Full Text]

Home page
 DTBHome page
Stopping panic attacks
DTB, August 1, 1997; 35(8): 58 - 62.
[Abstract] [Full Text] [PDF]